Pharnext Provides an Update on its Pivotal -2- finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(1)
Positive first results from the complete dose-finding part of a phase Ib/II study of tumor-agnostic NBTXR3 (PEP503) activated by radiotherapy with concurrent chemotherapy for patients with rectal cancer show that intratumoral injection of the product candidate was feasible and it was well tolerated at all dose levels
An injection procedure-related dose-limiting toxicity of urinary tract infection was observed in the study, however there were no observed adverse events or severe adverse events associated with NBTXR3
More than 70% of patients showed objective tumor response after concurrent chemoradiation
Approximately 90% of patients underwent total mesorectal excision (surgery), and 17.6% achieved pathological complete response
-18%
En 2020, Safe Orthopaedics turnover was 3 839 K€, down 18% compared to 2019, fully due to the impact of the global pandemic in 2020. However, the annual direct sales show, in spite of the lockdowns in Europe and in particular the French « white plan » limiting the hospitalizations because of the over-occupation of intensive care beds by covid patients, a growth of 9%. This is explained, in part, by the market penetration of Sterispine
TM PS 2
nd generation launched in 2020 and by the acquisition in LCI Medical in July 2020 and renamed in January 2021.
-22%
The group has undergone its strongest decrease in sales during the second quarter of 2020, 650k€ during the first lockdown, versus 964k€ during the second quarter of 2019, then resumed and upward trend in the third and fourth quarters, the latter being to be compared with the sales of the fourth quarter of 2019 equal to 1 502k€, the highest historical level, just before the pandemic.
Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering
Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021
Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study evaluating NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in the second quarter of 2021
The Company s expansive global development plan for NBTXR3, both as a single agent activated by radiotherapy and in combination with other anti-cancer therapies, will continue as planned
First drawing of a tranche of OCEANE from the bond financing line announced on December 17, 2020
December 24, 2020 02:30 ET | Source: Safe Orthopaedics Safe Orthopaedics Éragny, FRANCE
French
Éragny-sur-Oise, France, December 24, 2020, 8h30 CET – Safe Orthopaedics (FR0013467123 - ALSAF), a company specializing in the design, manufacturing and marketing of single-use technologies for spinal surgeries, delivering the safest treatment for spinal fractures urgently treated,
announces the execution of the flexible bond financing line announced on December 17, 2020 broken down in 24 degressive OCEANE tranche, with the Luxembourg investment fund European High Growth Opportunities Securitization Fund (the “
Investor”), by issuance of 1.680 Tranche Warrants for bonds convertible or exchangeable into new and/or existing shares with a part value of 5.000 € each (the “